Merck & Co., Inc., announces formation of new spin-off Organon

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) announced it has filed a Form 10 registration statement with the US Securities and Exchange Commission in relation to its intended biosimilars and women’s health spinoff, Organon. Merck & Co., Inc., announced that Organon will function as a standalone, publicly traded company, with separation on track to be completed late in Q2 2021.